Department of Surgery and Transplantation, Swiss HPB & Transplant Center Zurich, University Hospital Zurich, Zurich, Switzerland.
Department of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland.
Langenbecks Arch Surg. 2023 Jan 24;408(1):59. doi: 10.1007/s00423-023-02803-w.
Compression syndromes of the celiac artery (CAS) or superior mesenteric artery (SMAS) are rare conditions that are difficult to diagnose; optimal treatment remains complex, and symptoms often persist after surgery. We aim to review the literature on surgical treatment and postoperative outcome in CAS and SMAS syndrome.
A systematic literature review of medical literature databases on the surgical treatment of CAS and SMAS syndrome was performed from 2000 to 2022. Articles were included according to PROSPERO guidelines. The primary endpoint was the failure-to-treat rate, defined as persistence of symptoms at first follow-up.
Twenty-three studies on CAS (n = 548) and 11 on SMAS (n = 168) undergoing surgery were included. Failure-to-treat rate was 28% for CAS and 21% for SMAS. Intraoperative blood loss was 95 ml (0-217) and 31 ml (21-50), respectively, and conversion rate was 4% in CAS patients and 0% for SMAS. Major postoperative morbidity was 2% for each group, and mortality was described in 0% of CAS and 0.4% of SMAS patients. Median length of stay was 3 days (1-12) for CAS and 5 days (1-10) for SMAS patients. Consequently, 47% of CAS and 5% of SMAS patients underwent subsequent interventions for persisting symptoms.
Failure of surgical treatment was observed in up to every forth patient with a high rate of subsequent interventions. A thorough preoperative work-up with a careful patient selection is of paramount importance. Nevertheless, the surgical procedure was associated with a beneficial risk profile and can be performed minimally invasive.
腹腔动脉(CAS)或肠系膜上动脉(SMAS)压迫综合征是罕见的疾病,难以诊断;最佳治疗方法仍然很复杂,手术后症状常常持续存在。我们旨在回顾 CAS 和 SMAS 综合征的手术治疗和术后结果的文献。
对 2000 年至 2022 年期间 CAS 和 SMAS 综合征手术治疗的医学文献数据库进行了系统的文献回顾。根据 PROSPERO 指南纳入了文章。主要终点是治疗失败率,定义为首次随访时症状持续存在。
纳入了 23 项关于 CAS(n=548)和 11 项关于 SMAS(n=168)手术的研究。CAS 的治疗失败率为 28%,SMAS 的治疗失败率为 21%。术中出血量分别为 95ml(0-217)和 31ml(21-50),CAS 患者的转化率为 4%,SMAS 患者为 0%。每组的主要术后发病率为 2%,死亡率在 CAS 患者中为 0%,SMAS 患者中为 0.4%。CAS 患者的中位住院时间为 3 天(1-12),SMAS 患者为 5 天(1-10)。因此,47%的 CAS 患者和 5%的 SMAS 患者因持续存在症状而接受了后续干预。
多达每四个接受手术治疗的患者治疗失败,后续干预的发生率很高。因此,术前进行彻底的评估和仔细的患者选择至关重要。尽管如此,该手术程序与有益的风险特征相关,并且可以进行微创治疗。